Healthtech startup Temple has acquired Longevous, a London-based longevity medicine practice, as announced by Temple founder Deepinder Goyal on August 27. The acquisition precedes the planned launch of Temple’s wearable device, designed to track cerebral blood flow and oxygenation in real time. Financial terms of the deal were not disclosed, according to medianama.com.
The founders of Longevous, Dr Robert Mohr and Dr Avi Roy, along with their team, will join Temple full-time. Dr Mohr will take on the role of Chief Medical Officer at Temple. Mohr is a board-certified physician with nearly 20 years of clinical experience, having transitioned from emergency medicine to evidence-based preventive and precision medicine. Goyal highlighted that the Longevous team’s clinical expertise and publication experience will support Temple’s in-house team ahead of the device launch.
Temple’s wearable device was first reported in November 2025, with the goal of continuously monitoring cerebral blood flow and oxygenation levels. The acquisition of Longevous adds a clinical dimension to Temple’s offering, potentially enhancing its credibility and effectiveness in the longevity healthtech market. This move aligns with broader trends in wearable health devices integrating clinical research and personalized medicine.
Temple’s acquisition of Longevous was confirmed on August 27, 2026, with the Longevous founders joining the company immediately. The next key milestone for Temple is the launch of its wearable device, which will leverage the combined expertise of both teams to deliver real-time cerebral health monitoring.